Literature DB >> 978395

Nonlinear assessment of phenytoin bioavailability.

W J Jusko, J R Koup, G Alván.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 978395     DOI： 10.1007/BF01063122

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


× No keyword cloud information.
  9 in total

1.  Bioavailability and single-dose pharmacokinetics of intramuscular phenytoin.

Authors:  H B Kostenbauder; R P Rapp; J P McGovren; T S Foster; D G Perrier; H M Blacker; W C Hulon; A W Kinkel
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Bioavailability of diphenylhydantoin.

Authors:  K S Albert; E Sakmar; M R Hallmark; D J Weidler; J G Wagner
Journal:  Clin Pharmacol Ther       Date:  1974-10       Impact factor: 6.875

3.  Pharmacokinetics of single and multiple doses of phenytoin in man.

Authors:  L Lund; G Alvan; A Berlin; B Alexanderson
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

4.  Bioavailability, clinical effectiveness, and the public interest.

Authors:  G Levy
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

5.  Relationship between dose and plateau levels of drugs eliminated by parallel first-order and capacity-limited kinetics.

Authors:  T Tsuchiya; G Levy
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

6.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.

Authors:  N Gerber; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-05

7.  Phenytoin dose adjustment in epileptic patients.

Authors:  G E Mawer; P W Mullen; M Rodgers; A J Robins; S B Lucas
Journal:  Br J Clin Pharmacol       Date:  1974-04       Impact factor: 4.335

8.  Phenytoin: pharmacokinetics and bioavailability.

Authors:  R Gugler; C V Manion; D L Azarnoff
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

9.  Diphenylhydantoin elimination kinetics in overdosed children.

Authors:  L K Garrettson; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875
  9 in total
  27 in total

1.  Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs.

Authors:  Anne Dubois; Sandro Gsteiger; Etienne Pigeolet; France Mentré
Journal:  Pharm Res       Date:  2009-10-30       Impact factor: 4.200

2.  Evaluation of a bayesian pharmacokinetic program for phenytoin concentration predictions in outpatient population.

Authors:  J M Gaulier; R Boulieu; C Fischer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

3.  Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.

Authors:  Ali-Akbar Golabchifar; Saeed Rezaee; Nahid Mobarghei Dinan; Abbas Kebriaeezadeh; Mohammad-Reza Rouini
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

4.  Application of mean residence-time concepts to pharmacokinetic systems with noninstantaneous input and nonlinear elimination.

Authors:  H Y Cheng; W J Jusko
Journal:  Pharm Res       Date:  1989-01       Impact factor: 4.200

5.  Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism.

Authors:  G M Rubin; J A Waschek; S M Pond; D J Effeney; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

6.  Non-linear elimination and protein binding of probenecid.

Authors:  B M Emanuelsson; B Beermann; L K Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose.

Authors:  J J Crowley; J R Koup; B J Cusack; T M Ludden; R E Vestal
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Individual differences in the disposition of drugs metabolised in the body.

Authors:  G Alvan
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

9.  A comparison between microcrystalline and conventional phenytoin preparations: relative bioavailability and steady-state plasma concentrations.

Authors:  L O Boréus; A Nergårdh; M Ehrnebo; K Theorell
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

10.  Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.

Authors:  Yushi Inoue; Naotaka Usui; Tadayuki Hiroki; Kenji Shimizu; Susumu Kobayashi; Shigeki Shimasaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-09-12       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.